Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 17/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373625 | 0.90 | CXCR3 (0.57) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373631 | 0.88 | CXCR3 (0.55) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373619 | 0.87 | CLK2 (0.60) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373642 | 0.87 | CXCR3 (0.54) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373324 | 0.86 | CXCR3 (0.74) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373645 | 0.86 | CXCR3 (0.74) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL5454026 | 0.85 | CXCR3 (0.54) | CXCR3CLK2DYRK1ACLK4 | |
| SCHEMBL14373638 | 0.84 | CXCR3 (0.50) | CXCR3TP53MAPTTSHRMAPK1 | |
| SCHEMBL14373415 | 0.83 | CXCR3 (0.65) | CXCR3 | |
| SCHEMBL14373639 | 0.82 | CXCR3 (0.64) | CXCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885TP53 461/4885MAPT 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.